RxDoctor Payments Data

Enrique Villavicencio Sumire, MD

Neurology · Sikeston, MONPI 1386027506

Payments from drug & device makers

$5,302in general payments, 2019–2025

Across 297 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$802
  • Teva Pharmaceuticals USA, Inc.$390
  • UCB, Inc.$293
  • Lundbeck LLC$248
  • Lilly USA, LLC$158
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,07896%
  • Education$2244%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,302 in reported general payments places this provider in the 65th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$76,257
Medicare patients
364
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab18$154,106
Emgality PenGalcanezumab-Gnlm153$112,624
Aimovig AutoinjectorErenumab-Aooe96$72,996
QuliptaAtogepant58$67,938
Emgality SyringeGalcanezumab-Gnlm71$66,818
Nurtec OdtRimegepant Sulfate58$65,808
AptiomEslicarbazepine Acetate39$64,357
UbrelvyUbrogepant19$27,169
BotoxOnabotulinumtoxina19$24,536
NeuproRotigotine15$16,069
EliquisApixaban25$15,997
Carbidopa-LevodopaCarbidopa/Levodopa301$7,549
Rasagiline Mesylate27$3,721
Pregabalin167$3,552
Levetiracetam166$3,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Botox$1,092$119,64396 claims
PfizerNurtec Odt, Eliquis$96$81,80583 claims
Sunovion Pharmaceuticals Inc.Aptiom$17$64,35739 claims
UCB, Inc.Neupro$293$16,06915 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$59$1,05032 claims
Lilly USA, LLCOlanzapine$158$80136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 381 neurology providers in Missouri.

Other neurology in Sikeston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →